Investigating how specific bone cells influence breast cancer growth and spread
Role of Osterix+ Osteolineage Cells in Primary and Metastatic Breast Cancer
['FUNDING_R01'] · WASHINGTON UNIVERSITY · NIH-11026446
This study is looking at special bone cells in breast cancer to see how they might help tumors grow and spread, and it aims to find new ways to treat the disease by understanding how these cells interact with cancer.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WASHINGTON UNIVERSITY (nih funded) |
| Locations | 1 site (SAINT LOUIS, UNITED STATES) |
| Trial ID | NIH-11026446 on ClinicalTrials.gov |
What this research studies
This research explores the role of Osterix+ osteolineage cells in the tumor microenvironment of breast cancer. It examines how these cells, which are typically involved in bone formation, may contribute to the growth and metastasis of breast tumors by creating a supportive environment. The study involves analyzing tissue samples from breast cancer patients and using animal models to understand the interactions between these cells and cancer cells. By identifying the mechanisms through which these cells affect tumor behavior, the research aims to uncover new therapeutic targets.
Who could benefit from this research
Good fit: Ideal candidates for this research include adults diagnosed with breast cancer, particularly those with advanced or metastatic disease.
Not a fit: Patients with early-stage breast cancer or those not expressing Osterix+ cells may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for treating breast cancer by targeting the supportive cells in the tumor environment.
How similar studies have performed: Previous research has shown that targeting the tumor microenvironment can improve cancer treatment outcomes, suggesting that this approach may also be promising.
Where this research is happening
SAINT LOUIS, UNITED STATES
- WASHINGTON UNIVERSITY — SAINT LOUIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: FACCIO, ROBERTA — WASHINGTON UNIVERSITY
- Study coordinator: FACCIO, ROBERTA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer therapy